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Summary
Background: Vitamin D deficiency in early life might affect the developing lung and 
immune system, and subsequently influence the risk of asthma and allergy in later 
life.
Objective: We examined the associations of 25‐hydroxyvitamin D concentrations in 
mid‐gestation and at birth with lung function, asthma, inhalant allergic sensitization 
and inhalant allergy at school‐age.
Methods: This study among 4951 children and their mothers was embedded in a 
population‐based prospective cohort in Rotterdam, the Netherlands. Maternal ve‐
nous blood samples in mid‐gestation and umbilical cord blood samples at birth were 
used to determine 25‐hydroxyvitamin D concentrations. At age 10 years, lung func‐
tion was measured by spirometry, current asthma and physician‐diagnosed inhalant 
allergy by questionnaire, and inhalant allergic sensitization by skin prick tests. We 
used multivariable regression models to examine associations.
Results: Higher 25‐hydroxyvitamin D concentrations in mid‐gestation were associ‐
ated with a higher forced vital capacity (FVC), but a lower forced expiratory volume 
in 1 second/FVC (FEV1/FVC) and a lower forced expiratory flow after exhaling 75% 
of FVC (FEF75) (Z‐score differences [95% CI] 0.02 [0.00, 0.03], −0.02 [−0.03, −0.01] 
and −0.01 [‐0.03, −0.00], respectively, per 10 nmol/L 25‐hydroxyvitamin D), but not 
with asthma. Furthermore, higher 25‐hydroxyvitamin D concentrations in mid‐gesta‐
tion were associated with an increased risk of inhalant allergy (Odds Ratio [95% CI] 
1.07 [1.02, 1.12]), but not with inhalant allergic sensitization. After additional adjust‐
ment for child's 25‐hydroxyvitamin D concentrations at the age of 6 years, only the 
associations of 25‐hydroxyvitamin D concentrations in mid‐gestation with FEV1/
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1  | INTRODUC TION
Fetal vitamin D deficiency might have adverse effects on the de‐
veloping lung and immune system, and subsequently influence lung 
function, and the risk of asthma and allergy in later life.1,2 Vitamin D 
deficiency during pregnancy may alter the expression of genes as‐
sociated with asthma in children,3 potentially through their roles in 
lung development and airway branching morphogenesis.3,4 Vitamin 
D might also have immunomodulatory effects in utero, including 
inhibition of fetal Th2 responses, which might affect the develop‐
ment of asthma and allergy in childhood.5 A combined analysis of 
two randomized controlled trials showed that high‐dose vitamin D 
supplementation in pregnancy reduced the risk of asthma with 26% 
in pre‐school children.6 Three meta‐analyses of prospective cohort 
studies on the associations of early life 25‐hydroxyvitamin D con‐
centrations with respiratory and allergy outcomes in children found 
inconsistent results.7‐9 One meta‐analysis reported that lower and 
higher 25‐hydroxyvitamin D concentrations during pregnancy were 
associated with an increased risk of childhood asthma, with the 
lowest risk at a 25‐hydroxyvitamin D concentration of 70 nmol/L,7 
while others did not find consistent associations with asthma,8,9 
lung function9 or allergic sensitization.9 However, studies included 
in these meta‐analyses used only one single assessment of 25‐hy‐
droxyvitamin D at different time‐points during pregnancy or at 
birth, or were not able to take child's 25‐hydroxyvitamin D into 
account,10 which may explain the inconsistency. We previously 
observed that lower 25‐hydroxyvitamin D concentrations at birth 
were associated with a higher airway resistance in children aged 
6 years, adjustment for child's 25‐hydroxyvitamin D reduced the 
effect size.11
We hypothesized that altered 25‐hydroxyvitamin D concen‐
trations in critical periods of early life are associated with adverse 
childhood respiratory and allergy outcomes. Therefore, we exam‐
ined among 4951 children and their mothers participating in a popu‐
lation‐based prospective cohort study, whether 25‐hydroxyvitamin 
D concentrations in mid‐gestation and at birth were associated with 
lung function, asthma, inhalant allergic sensitization and inhalant 
allergy in school‐age children. Additionally, we examined whether 
these associations could be explained by child's 25‐hydroxyvitamin 
D concentrations at the age of 6 years.
2  | METHODS
2.1 | Design and cohort
This study was embedded in the Generation R Study, a popula‐
tion‐based prospective cohort study from early fetal life until young 
adulthood in Rotterdam, the Netherlands. A detailed description 
of the study design has been published previously.12 The study 
has been approved by the Medical Ethical Committee of Erasmus 
MC, University Medical Centre in Rotterdam, the Netherlands 
(MEC‐2012‐165‐NL40020.078.12). Written informed consent was 
obtained from the parents or legal representatives of all participat‐
ing children. A total of 7393 children were participating at the age 
of 10 years. Twins (n = 185), and children of whom we had no data 
on 25‐hydroxyvitamin D concentrations in mid‐gestation or at birth 
(n = 1171), and children with missing data on lung function, asthma, 
inhalant allergic sensitization or inhalant allergy at age 10 years 
(n = 1086) were excluded. This resulted in 4951 mothers and their 
children for the current analyses (Figure S1).
2.2 | 25‐Hydroxyvitamin D
Maternal venous blood samples were obtained in mid‐gesta‐
tion (median 20.4 [95% range 18.5‐23.4] weeks of gestation) and 
umbilical cord blood samples at birth (median 40.3 [95% range 
36.7‐42.3] weeks of gestation).13 Concentrations of 25‐hydroxy‐
vitamin D were analysed from stored frozen samples at −80°C at 
the Eyles Laboratory at the Queensland Brain Institute, University 
of Queensland, Australia. Samples were quantified using isotope di‐
lution liquid chromatography/tandem mass spectrometry (LC‐MS/
MS).14 25‐Hydroxyvitamin D concentrations were analysed both 
continuously and in groups based on clinical cut‐offs defined as “se‐
verely deficient” (<25.0 nmol/L [<10.0 mg/L]), “deficient” (25.0 to 
<50.0 nmol/L [10.0 to <20.0 mg/L]) and “sufficient” (≥50.0 nmol/L 
[≥20.0 mg/L]).15 When the children had a median age of 6.0 years 
(95% range 5.6‐7.6 years), blood samples were collected. Child's 25‐
hydroxyvitamin D concentrations were measured at the Endocrine 
Laboratory of the VU University Medical Center, Amsterdam, using 
isotope dilution online solid phase extraction LC‐MS/MS, which has 
been previously described in detail.16 25‐Hydroxyvitamin D status 
at the age of 6 years was available in a subgroup of 2809 subjects.
FVC and FEF75 remained. We did not find consistent associations of 25‐hydroxyvita‐
min D concentrations at birth with respiratory or allergy outcomes.
Conclusion and clinical relevance: Our results suggest that maternal 25‐hydroxyvita‐
min D concentrations in mid‐gestation may influence lung development. The clinical 
implications of the observed associations remain unclear.
K E Y W O R D S
asthma, child, inhalant allergic sensitization and allergy, lung function, prospective cohort 
study, vitamin D
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2.3 | School‐age lung function, asthma and 
allergy outcomes
Children visited our research centre at a median age of 9.7 years 
(95% range 9.4‐10.8 years). Spirometry was performed according to 
the American Thoracic Society and European Respiratory Society 
recommendations.17 Lung function measures included forced expir‐
atory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/
FVC and forced expiratory flow after exhaling 75% of FVC (FEF75), 
and were converted into sex‐, height‐, age‐ and ethnicity‐adjusted z‐
scores according to the Global Lung Initiative reference data.18 Only 
pre‐bronchodilation lung function measurements were available in 
this study. Additionally, we included 342 children with spirometry 
curves with a >5% deviation, but with at least one blow (according 
to ATS/ERS criteria) with adequate reach and duration of plateau. 
We observed no difference in the size or direction of the effect es‐
timates in our analyses when we included these children.19 Children 
were asked to stop the use of short‐acting bronchodilators 8 hours, 
and long‐acting bronchodilators 48 hours before spirometry, if they 
did not suffer from asthma symptoms. Contraindications for spirom‐
etry were a current acute asthma attack or respiratory tract infec‐
tion. At age 10 years, information on ever asthma (no; yes), current 
wheezing (no; yes) and on physician‐diagnosed inhalant allergy (no; 
yes) to pollen (hay fever), house dust mite, cat or dog was obtained 
from questionnaires based on the International Study on Asthma 
and Allergy in Childhood (ISAAC) Questionnaire.20 Information on 
asthma medication use (no; yes) was obtained during the visit at 
the research centre. Current asthma (no; yes) was defined as ever 
diagnosis of asthma with either wheezing or medication use in the 
past 12 months at age 10 years. At age 10 years, inhalant allergic 
sensitization (no; yes) to house dust mite, five‐grass mixture, birch, 
cat or dog (ALK‐Abelló BV, Almere, the Netherlands) was measured 
by skin prick tests using the scanned area method.21 We used two 
positive controls (histamine dihydrochloride 10 mg/mL) and one 
negative control (sodium chloride 9 mg/mL). Skin responses were 
considered positive if the area of the wheal was ≥40% of that of 
the histamine response (ie histamine equivalent prick index area 
≥0.40).21 Contraindications for a skin prick test were eczema on the 
volar surface of the left forearm, the use of oral prednisone ≥10 mg 
daily, antihistamine intake <72 hours prior to the test or use of corti‐
costeroid ointment ≤48 hours prior to the test.
2.4 | Covariates
Information on maternal age, body mass index at enrolment (BMI), 
educational level, history of asthma or atopy, psychiatric symptoms 
defined using the Global Severity Index (GSI),22,23 parity, smoking, 
pet keeping and damp patches or mould in the house, was obtained 
from questionnaires during pregnancy. Maternal folate concentra‐
tions were measured in early pregnancy (median 13.2 [95% range 
9.8‐17.4] weeks of gestation) as previously described.24 Season of 
blood sampling was recorded at the moment of blood sampling of 
25‐hydroxyvitamin D. Midwife or hospital records at birth provided 
information about child's sex, gestational age at birth and birth 
weight. Child's ethnic background was categorized on the basis of 
expected similarities in skin colour into Dutch and Western (Dutch, 
other European, American and Oceanian), Turkish and Moroccan, 
African (Cape Verdean, other African, Surinamese‐Creole and Dutch 
Antillean) and Asian (Indonesian, other Asian, Surinamese‐Hindu 
and Surinamese‐unspecified).16 Information on ever breastfeeding 
and day care attendance was obtained by multiple questionnaires.
2.5 | Statistical analysis
A non‐response analysis was performed by comparing subject char‐
acteristics between children included and not included in the analy‐
ses by independent sample t test for continuous normally distributed 
variables, Mann‐Whitney U test for continuous not normally dis‐
tributed variables, and chi‐square test for categorical variables. We 
calculated Spearman's correlation coefficients for the correlations 
between 25‐hydroxyvitamin D concentrations in mid‐gestation, at 
birth and at the age of 6 years. We used linear or logistic regression 
models to examine the associations of mid‐gestational and cord blood 
25‐hydroxyvitamin D concentrations with lung function, asthma, in‐
halant allergic sensitization and inhalant allergy. 25‐Hydroxyvitamin 
D concentrations were analysed as a continuous variable and in cat‐
egories based on clinical cut‐off values, and additionally in categories 
based on tertiles. Model 1 (main model) was adjusted for the con‐
founders maternal age, BMI at enrolment, educational level, history 
of asthma or atopy, psychiatric symptoms, parity, smoking during 
pregnancy, pet keeping, damp patches or mould in the house, folate 
concentration, and season of blood sampling, and child's sex, gesta‐
tional age at birth, birth weight, ethnic background, breastfeeding 
and day care attendance. Potential confounders were included in our 
models based on literature, if they were related to both 25‐hydroxy‐
vitamin D concentrations and at least one of the outcomes, or if the 
effect estimate changed ≥10% when we included the covariate in 
the model. Model 2 (child 25‐hydroxyvitamin D model) comprised 
the main model and was additionally adjusted for 25‐hydroxyvitamin 
D concentrations at the age of 6 years. We adjusted childhood 25‐
hydroxyvitamin D concentrations for the season of blood sampling 
using the residual method. We performed sensitivity analyses to test 
the robustness of our results. First, to prevent confounding or ef‐
fect modification by heterogeneous groups with a non‐Dutch ethnic 
background with different skin types and dietary habits, we repeated 
the main analyses restricted to children with a Dutch ethnic back‐
ground. Second, we restricted our analyses on the associations of 
25‐hydroxyvitamin D as a continuous variable with respiratory and 
allergy outcomes to mothers and children with severely deficient and 
deficient concentrations in mid‐gestation or at birth. Third, for clini‐
cal interpretation we studied the associations of 25‐hydroxyvitamin 
D concentrations with the risk of lung function outcomes below the 
lower limit of normal defined as lower than the 2.5th centile (z‐score 
−1.96).18 We tested for multicollinearity using the tolerance statistic. 
As tolerance was >0.20 for all variables in our models, there were 
no problems of multicollinearity. We applied natural cubic splines 
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(3 degrees of freedom) to test for non‐linearity of the associations 
of 25‐hydroxyvitamin D concentrations with outcomes in our main 
models. Except for the associations of 25‐hydroxyvitamin D concen‐
trations at birth with FVC and FEV1/FVC, no better fit for a non‐lin‐
ear model vs a linear model was found. Therefore, we considered 
linear models to be the most suitable for our main analyses. Missing 
data for covariates were <20% except for maternal folate concentra‐
tions (27.1%) and child's day care attendance (37.4%). To reduce bias 
and imprecision, we imputed missing data of the covariates with mul‐
tiple imputations (m = 10) using chained equations. All measures of 
association are presented as pooled effect estimates with their 95% 
confidence intervals (95% CI). Statistical analyses were performed 
using SPSS version 24.0 for Windows (IBM Corp., Armonk, NY, USA) 
and R version 3.5.0 (R Foundation, Vienna, Austria).
3  | RESULTS
3.1 | Subject characteristics
Maternal and child characteristics are shown in Table 1. The me‐
dian 25‐hydroxyvitamin D concentration in mid‐gestation was 
53.0 nmol/L (95% range 8.1‐122.5) and at birth 30.7 nmol/L (95% 
range 5.3‐82.7). Mean FEV1 Z‐score (SD) was 0.17 (0.98), FVC 0.21 
(0.94), FEV1/FVC −0.09 (0.95) and FEF75 0.05 (0.92). The prevalence 
of current asthma was 5.7% (n = 226), of inhalant allergic sensitiza‐
tion 32.9% (n = 1131) and of physician‐diagnosed inhalant allergy 
13.3% (n = 369). Non‐response analyses showed that children who 
were not included in the analyses on average had mothers who were 
younger, had a higher BMI, were lower educated, were less often 
nulliparous, had less often pets and had lower folate concentrations 
in early pregnancy, and the children had more often not a Dutch or 
Western ethnic background compared to children included in the 
analyses (P‐value < 0.05) (Table S1). Non‐response analyses compar‐
ing children with and without information on 25‐hydroxyvitamin D 
concentrations at the age of 6 years most importantly showed that 
there was no difference in 25‐hydroxyvitamin D concentrations in 
mid‐gestation and at birth between the two groups (Table S2).
3.2 | 25‐hydroxyvitamin D concentrations, 
respiratory and allergy outcomes
Maternal 25‐hydroxyvitamin D concentration in mid‐gestation mod‐
erately correlated with child's 25‐hydroxyvitamin D level at birth 
(ρ = 0.579; P < 0.001) and at the age of 6 years (ρ = 0.300; P < 0.001). 
A higher maternal 25‐hydroxyvitamin D concentration in mid‐gesta‐
tion was associated with a higher FVC (Z‐score difference [95% CI] 
0.02 [0.00, 0.03] per 10 nmol/L), but a lower FEV1/FVC (Z‐score dif‐
ference −0.02 [−0.03, −0.01]) and FEF75 (Z‐score difference −0.01 
[−0.03, −0.00]) at school‐age (Table 2). After additional adjustment 
for 25‐hydroxyvitamin D concentrations at the age of 6 years, the 
association of maternal 25‐hydroxyvitamin D concentrations in mid‐
gestation with FVC attenuated into non‐significant. Furthermore, 
a higher 25‐hydroxyvitamin D concentration in mid‐gestation was 
associated with a higher risk of inhalant allergy (Odds Ratio [OR] 
[95% CI] 1.07 [1.02, 1.12] per 10 nmol/L), but attenuated into non‐
significant when 25‐hydroxyvitamin D concentrations at the age of 
6 years were taken into account. We observed similar, but no con‐
sistent trends when we studied 25‐hydroxyvitamin D in categories 
based on clinical cut‐offs. Maternal 25‐hydroxyvitamin D concentra‐
tions in mid‐gestation were not associated with asthma or inhalant 
allergic sensitization.
25‐Hydroxyvitamin D concentrations at birth were not con‐
sistently associated with any lung function measure, asthma, in‐
halant allergic sensitization or inhalant allergy in our main model 
(Table 3). We only observed that children with severely deficient 25‐
hydroxyvitamin D concentrations at birth had a lower FVC (Z‐score 
difference −0.12 [−0.23, −0.02]) compared to children with suffi‐
cient concentrations. This attenuated into non‐significant after ad‐
ditional adjustment for 25‐hydroxyvitamin D concentrations at the 
age of 6 years. When we studied 25‐hydroxyvitamin D concentra‐
tions both in mid‐gestation and at birth in groups based on tertiles, 
we observed similar directions of the results compared to the groups 
based on clinical cut‐off values (Tables S3 and S4).
When we repeated our analyses in only children with a Dutch 
ethnic background, we observed similar directions of the effects of 
25‐hydroxyvitamin D concentrations in mid‐gestation and at birth 
on respiratory and allergy outcomes (Tables S5 and S6). We ob‐
served associations of higher 25‐hydroxyvitamin D concentrations 
in mid‐gestation with a higher risk of inhalant allergic sensitization 
and inhalant allergy (OR 1.06 [1.02, 1.10] and 1.09 [1.03, 1.16]), but 
both effect estimates attenuated into non‐significant when 25‐hy‐
droxyvitamin D concentration at the age of 6 years was taken into 
account. In a sensitivity analysis restricted to mothers or children 
with severely deficient or deficient levels in mid‐gestation or at 
birth, we observed similar associations as in the total group (data 
not shown). When we studied the associations of 25‐hydroxyvita‐
min D concentrations with the risk of lung function outcomes below 
the lower limit of normal, we only observed that a higher 25‐hy‐
droxyvitamin D concentration at birth was associated with a lower 
risk of a z‐score below the lower limit of normal for FVC (OR 0.77 
[0.61, 0.97]). This association attenuated after adjustment for 25‐hy‐
droxyvitamin D at the age of 6 years (data not shown).
4  | DISCUSSION
In this population‐based prospective cohort study, we observed that 
higher maternal 25‐hydroxyvitamin D concentrations in mid‐ges‐
tation were associated with a higher FVC, but a lower FEV1/FVC 
and FEF75, and with a higher risk of physician‐diagnosed inhalant al‐
lergy in children at school‐age. Observed associations were partly 
explained by 25‐hydroxyvitamin D concentrations at the age of 
6 years, and less prominent when studying 25‐hydroxyvitamin D 
in groups based on clinical cut‐off values. We did not find any con‐
sistent associations of 25‐hydroxyvitamin D concentrations at birth 
with respiratory or allergy outcomes.
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4.1 | Comparison with previous studies
We found that higher 25‐hydroxyvitamin D concentrations in mid‐
gestation, but not at birth, were associated with a higher FVC but 
a lower FEV1/FVC and FEF75. A recent meta‐analysis pooled the 
results of 4 cohort studies with 292‐3784 participants and found 
no associations of maternal 25‐hydroxyvitamin D concentrations 
during pregnancy with FEV1 or FVC in childhood. However, they 
combined 25‐hydroxyvitamin D concentrations obtained at differ‐
ent time‐points in pregnancy or at birth into one exposure variable.9 
One cohort study, which was included in the meta‐analysis, meas‐
ured maternal 25‐hydroxyvitamin D concentrations at a similar 
time‐point in pregnancy, mid‐gestation, as we did and showed that 
higher maternal 25‐hydroxyvitamin D concentrations in mid‐gesta‐
tion were associated with a higher FVC and a tendency towards 
a lower FEV1/FVC and FEF25%‐75% in 260 children aged 6 years.
25 
The directions of the effect estimates in our study were similar. 
Cohort studies within the meta‐analysis that examined maternal 
25‐hydroxyvitamin D concentrations in late pregnancy,26‐28 and 
one additional high‐risk cohort study (n = 257) that examined 25‐
hydroxyvitamin D concentrations at birth,29 found no associations 
with lung function measures, as we did. These findings underline 
the importance of the differences in effects of 25‐hydroxyvitamin 
D concentrations measured in different periods of pregnancy on 
fetal lung development.
We observed no consistent associations of maternal 25‐hy‐
droxyvitamin D concentrations in mid‐gestation and at birth with 
the risk of asthma in children. These findings are in line with two 
meta‐analyses which pooled the results of population‐based or high‐
risk cohort studies with 186‐31778 and with 164‐20 800 children.9 
However, an additional meta‐analysis pooled studies with 164‐3177 
children and found that lower and higher maternal 25‐hydroxyvita‐
min D concentrations taken at any time in pregnancy were associated 
TA B L E  1   Maternal and child characteristics
 n = 4951
Maternal characteristics
Age, y 30.7 (4.9)
Body mass index at enrolment (kg/m2)a 23.7 (18.7‐35.7)
Educational level, higher (%) 51.0 (2525)
History of asthma or atopy, yes (%) 39.0 (1932)
Psychiatric symptoms (GSI)a 0.17 (0.0‐1.26)
Parity, nullipara (%) 57.9 (2869)
Smoking during pregnancy, yes (%) 30.3 (1502)
Pet keeping, yes (%) 41.9 (2072)
Damp patches or mould in house, yes (%) 16.2 (804)
Folate concentration in early pregnancy, 
nmol/La
18.2 (4.1‐51.2)
Mid‐gestational blood sampling season (%)
Spring 31.0 (1537)
Summer 22.2 (1097)
Autumn 23.9 (1182)
Winter 22.9 (1135)
25‐Hydroxyvitamin D concentration in 
mid‐gestation (nmol/L)a
53.0 (8.1‐122.5)
Severely deficient (%) 20.1 (905)
Deficient (%) 26.1 (1178)
Sufficient (%) 53.8 (2424)
Child characteristics
Female sex (%) 50.6 (2504)
Gestational age at birth (weeks)a 40.1 (35.9‐42.3)
Birth weight (grams) 3449 (550)
Ethnic background (%)
Dutch and Western 70.1 (3471)
Turkish and Moroccan 11.3 (561)
African 10.8 (537)
Asian 7.7 (383)
Ever breastfeeding, yes (%) 88.3 (4372)
Day care attendance first year, yes (%) 61.6 (3049)
At birth blood sampling season (%)
Spring 24.1 (1192)
Summer 26.7 (1324)
Autumn 27.2 (1349)
Winter 21.9 (1086)
25‐Hydroxyvitamin D concentration at 
birth (nmol/L)a
30.7 (5.3‐82.7)
Severely deficient (%) 40.2 (1320)
Deficient (%) 37.4 (1229)
Sufficient (%) 22.4 (735)
25‐Hydroxyvitamin D concentration at the 
age of 6 y (nmol/L)a
65.6 (19.1‐134.8)
FEV1 (z‐score) 0.17 (0.98)
(Continues)
 n = 4951
FVC (z‐score) 0.21 (0.94)
FEV1/FVC (z‐score) −0.09 (0.95)
FEF75 (z‐score) 0.05 (0.92)
Current asthma at the age of 10 y, yes (%) 5.7 (226)
Inhalant allergic sensitization at the age of 
10 y, yes (%)
32.9 (1131)
Physician‐diagnosed inhalant allergy at the 
age of 10 y, yes (%)
13.3 (369)
Values are means (SD), amedians (2.5‐97.5th percentile) or valid 
percentages (absolute numbers), based on imputed data. Data on 
25‐hydroxyvitamin D in mid‐gestation (n = 444), at birth (n = 1667), at 
the age of 6 y (n = 2142), and forced expiratory volume in 1 s (FEV1) 
(n = 752), forced vital capacity (FVC) (n = 752), FEV1/FVC ratio (n = 752), 
forced expiratory flow after exhaling 75% of FVC (FEF75) (n = 752), 
current asthma (n = 1001), inhalant allergic sensitization (n = 1512) and 
physician‐diagnosed inhalant allergy (n = 2173) was not imputed. 
TA B L E  1   (Continued)
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with a higher risk of asthma in children.7 A combined analysis of two 
randomized controlled trials showed that women who received daily 
a high dose of vitamin D supplementation (4000 IU/d or 2400 IU/d) 
from a gestational age ranging from 10 to 26 weeks onwards had, 
compared to the control group of women who received placebo, a 
26% reduced risk of a child with asthma/recurrent wheeze at the 
age of 3 years.6 The meta‐analyses and randomized controlled tri‐
als mostly assessed asthma at a young age, which more likely could 
reflect viral induced wheezing.30 Our study additionally shows the 
long‐term effects of maternal 25‐hydroxyvitamin D concentrations 
in mid‐gestation and at birth on asthma in children, which was not 
present.
We found an association of higher 25‐hydroxyvitamin D concen‐
trations in mid‐gestation with a higher risk of physician‐diagnosed 
inhalant allergy, and in only children with a Dutch ethnic background, 
a higher risk of inhalant allergic sensitization. However, these find‐
ings were explained by 25‐hydroxyvitamin D concentrations at the 
age of 6 years. Previous studies observed no associations of 25‐hy‐
droxyvitamin D concentrations in pregnancy with inhalant allergic 
sensitization or allergy in childhood,25‐27 but high 25‐hydroxyvita‐
min D concentrations (≥100 nmol/L) at birth were associated with an 
increased risk of skin prick test positivity for inhalant allergens (Odds 
Ratio 3.4 [1.0‐11.4]), compared to the reference group (75‐99.9 nmo‐
l/L).31 Child's 25‐hydroxyvitamin D concentrations were not taken 
into account. Effects of 25‐hydroxyvitamin D concentrations on al‐
lergic outcomes remain inconclusive.
4.2 | Interpretation of the results
The associations of maternal 25‐hydroxyvitamin D concentrations 
with lung function outcomes could be partly explained by the role 
of vitamin D in lung development. Our maternal venous blood sam‐
ples were taken in mid‐gestation, which might reflect the pseu‐
doglandular and canalicular stage of lung development.32 Genomic 
studies showed that 1,25‐dihydroxyvitamin D, the biologically ac‐
tive form, already in these stages of lung development influences 
the expression of genes, which have previously been associated 
with lung development and asthma pathogenesis.3 Furthermore, in 
vivo mice studies reported that in utero 25‐hydroxyvitamin D defi‐
ciency can result in a reduced lung volume,33 a diminished tracheal 
diameter and alveolar simplification,34 as well an altered lung func‐
tion33 with increased airway resistance and decreased pulmonary 
compliance.34 Our observations that higher 25‐hydroxyvitamin D 
concentrations are associated with a higher FVC are in line with 
these studies. We did not find an association with FEV1, which 
could explain the associations of higher 25‐hydroxyvitamin D con‐
centrations with a lower FEV1/FVC ratio. FEF75 might be used as 
predictor of small airways disease, but the importance is subject of 
debate.35 We need to be careful with a biological interpretation of 
the association of higher mid‐gestational 25‐hydroxyvitamin D con‐
centrations with lower FEF75 values, since development of smaller 
airways mostly occurs in later stages of pregnancy. The observed 
effects of 25‐hydroxyvitamin D concentrations per 10 nmol/L 
increase on lung function outcomes are minimal. Therefore, we 
cannot draw any conclusions other than that 25‐hydroxyvitamin D 
concentrations in mid‐gestation may influence lung development, 
but seem not related to the risk of clinically manifest lung function 
changes or childhood asthma. Umbilical cord blood samples at birth 
might reflect the third trimester of pregnancy, in which the alveo‐
lar stage of lung development and surfactant synthesis occurs.32,36 
However, our study showed no effect of maternal 25‐hydroxyvi‐
tamin D concentrations at birth on child's respiratory outcomes. 
Aside from its role in lung development, vitamin D might influence 
the immune system. The placenta may synthesize 1,25‐dihydroxy‐
vitamin D3, which suggest it could act as an autocrine or paracrine 
regulator of the developing fetal immune system already in the first 
trimester of pregnancy.37,38 Furthermore, 1,25‐dihydroxyvitamin 
D might have both stimulating and inhibitory effects on Th2 re‐
sponses, which effect might probably depend on the time period 
of exposure to 1,25‐dihydroxyvitamin D.39 In human cord blood 
cells, 1,25‐dihydroxyvitamin D has been shown to suppress IL‐4 
and IL‐4 induced IL‐13 expression,5 and in an in vivo mice study, 
perinatal 25‐hydroxyvitamin D deficiency resulted in Th2 skewing 
and increased airway eosinophilia.40 In five‐week‐old mice, results 
seemed different.41 The association of higher 25‐hydroxyvitamin 
D concentrations in mid‐gestation with physician‐diagnosed inhal‐
ant allergies attenuated after adjustment for 25‐hydroxyvitamin D 
concentrations at the age of 6 years. Additional research to the un‐
derlying mechanism at different time‐points during immune system 
development is needed.
4.3 | Strengths and limitations
The strengths of our study include that it was embedded in a pro‐
spective population‐based cohort study with a large sample‐size, 
and with detailed measurements on 25‐hydroxyvitamin D con‐
centrations at several time‐points in early life, and on respiratory 
and allergy outcomes. We were able to adjust our models for mul‐
tiple confounders, and additionally for 25‐hydroxyvitamin D lev‐
els at the age of 6 years. The adjustment for folate concentration 
and maternal psychiatric symptoms might be tenuous. However, 
omitting these two confounders from our statistical models did 
not change our results (data not shown). We also need to men‐
tion some limitations. Non‐response analyses showed a selection 
towards a relatively more healthy and economically advanced 
population. This selective non‐response could have led to biased 
effect estimates if the examined associations would differ be‐
tween children included and not included in the analyses. Second, 
25‐hydroxyvitamin D concentrations were used to quantify vi‐
tamin D status, which might reflect both diet and sun exposure. 
Currently, no cut‐off values are available to define vitamin D de‐
ficiency in pregnancy. For clinical interpretation and to make this 
study comparable to previous studies on vitamin D and asthma, 
we choose to define the groups based on current guidelines for 
clinical cut‐off values in the general population. A different ap‐
proach, when we studied 25‐hydroxyvitamin D in groups based 
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on tertiles showed similar results. 25‐Hydroxyvitamin D crosses 
the placenta,42 so the use of maternal 25‐hydroxyvitamin D con‐
centrations might be a good proxy for fetal 25‐hydroxyvitamin D 
status. However, although cord blood 25‐hydroxyvitamin D con‐
centrations correlate with maternal serum concentrations,43 they 
are on average 75% of maternal serum concentrations,43 meaning 
that we need to be careful to interchange maternal and fetal 25‐
hydroxyvitamin D values.44 Furthermore, the biologically active 
1,25‐dihydroxyvitamin D concentration rises during pregnancy, 
and the ratio of 1,25‐dihydroxyvitamin D/25‐hydroxyvitamin 
D might become twice as high as in non‐pregnant women,45 so 
25‐hydroxyvitamin D concentrations might not fully represent 
1,25‐dihydroxyvitamin D activity.45 Information on asthma and 
inhalant allergy was obtained from validated questions, adapted 
from the ISAAC Core Questionnaires. Nevertheless, reporting 
bias cannot be excluded which might lead to under‐ or overesti‐
mations of the observed associations. Last, residual confounding 
due to unmeasured factors including the intake of other nutri‐
ents or supplements might have influenced or even explain our 
results. During the recruitment period for this study (2002‐2006), 
the guidelines from the Health Council of the Netherlands sug‐
gested that all pregnant women should be advised to take 10 µg 
of vitamin D daily.46 Unfortunately, we had no detailed informa‐
tion on the intake of vitamin D from supplements for the current 
analyses and therefore cannot examine this potential effect on 
the observed associations. However, the observed 25‐hydroxyvi‐
tamin D concentrations in mid‐gestation and at birth are consist‐
ent with previous Dutch studies.47,48
5  | CONCLUSION
Our results suggest that, after additional adjustment for 25‐hydroxy‐
vitamin D at the age of 6 years, higher maternal 25‐hydroxyvitamin 
D concentrations in mid‐gestation are associated with a lower FEV1/
FVC and FEF75, but not with asthma. We did not find any consist‐
ent associations of 25‐hydroxyvitamin D concentrations at birth with 
respiratory or allergy outcomes. In line with the inconsistent results 
of previous observational studies, our study shows the complexity 
of the associations of early life vitamin D with respiratory and al‐
lergy outcomes. Further understanding of the mechanisms underly‐
ing the associations at different time‐points in early life is needed. 
Randomized controlled trials focusing on the effect of vitamin D sup‐
plementation in pregnancy or even pre‐conceptional on long‐term 
respiratory or allergy outcomes might be subject for further study.
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